AVVISO n. 224 24 marzo 2015 Mittente del comunicato: EuroTLX SIM Società oggetto dell'Avviso: --- Oggetto: RETTIFICA DENOMINAZIONE STRUMENTO EuroTLX Testo del comunicato EuroTLX comunica la rettifica della Denominazione Strumento come di seguito riportato: ISIN US09062X1037 Trading Code Instrument ID Denominazione Strumento BIIB-U 20793 BIOGEN EuroTLX SIM S.p.A. | Cap. Soc. € 5.000.000,00 i.v. - Iscritta al Registro delle Imprese di Milano - Codice Fiscale e Partita IVA n. 03421230966 | R.E.A. n. 1673989 | Autorizzata con delibera CONSOB n. 17099 del 15 dicembre 2009 | Aderente Fondo Nazionale di Garanzia | Società sottoposta all'attività di direzione e coordinamento di London Stock Exchange Group Holdings Italia S.p.A. Published on Biogen Media (ht t p://biogen.newshq.businesswire.com) on 3/23/15 6:00 am EDT Biogen Idec Becomes Biogen Release Date: Monday, March 23, 2015 6:00 am EDT T erms: Corporat e [1] Dateline City: CAMBRIDGE, Mass. New Corporate Identity and Brand Reflect Company’s Heritage and Commitment to Patients and Science CAMBRIDGE, Mass.--(BUSINESS WIRE [2] )--Effect ive t oday, Biogen Idec is known simply as Biogen [3] (NASDAQ: BIIB). The company has int roduced a new corporat e ident it y and logo t hat reflect bot h it s evolut ion and focus on bringing fort h new t herapies in areas of high unmet need – while honoring Biogen’s scient ific herit age and legacy as a pioneer in t he biot echnology indust ry. For more informat ion and t o read a let t er about t oday’s announcement [4] from Chief Execut ive Officer George A. Scangos, Ph.D., visit t he company’s new websit e at www.biogen.com [5] . Biogen Idec was creat ed in 2003 t hrough t he merger of Biogen and IDEC Pharmaceut icals, creat ing one of t he world’s leading research-based life sciences organizat ions. The company has since focused it s research and commercial effort s in t hree core areas: neurology, immunology and hemat ology. Biogen’s common st ock will cont inue t o t rade on t he Nasdaq Global Select Market under t he symbol “BIIB,” and it s CUSIP number will not change. Abo ut Bio gen Through cut t ing-edge science and medicine, Biogen discovers, develops and delivers t o pat ient s worldwide innovat ive t herapies for t he t reat ment of neurodegenerat ive diseases, hemat ologic condit ions and aut oimmune disorders. Founded in 1978, Biogen is one of t he world’s oldest independent biot echnology companies and pat ient s worldwide benefit from it s leading mult iple sclerosis and innovat ive hemophilia t herapies. For product labeling, press releases and addit ional informat ion about t he company, please visit www.biogen.com [6 ] . Language: English Contact: MEDIA CONTACT: Biogen Jason Glashow, +1-781-464-3260 [email protected] [7] or INVESTOR CONTACT: Carlo Tanzi, Ph.D., +1-781-464-2442 [email protected] [8] T icker Slug: Ticker: BIIB Exchange: NASDAQ ISIN: US09062X1037 Source URL: http://biogen.newshq.businesswire.com/press-release/corporate/biogen-idec-becomes-biogen Links: [1] http://biogen.newshq.businesswire.com/category/press-release-category/%5Bcatpath-raw%5D-0 [2] http://www.businesswire.com [3] http://cts.businesswire.com/ct/CT? id=smartlink&url=http%3A%2F%2Fwww.biogen.com&esheet=51063452&newsitemid=20150323005258&lan=enUS&anchor=Biogen&index=1&md5=00bf31e6853265a6eae0617e79d3fedd [4] http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.biogen.com%2Fen_us%2Fnewsinsights%2Fperspectives%2Fperspectives-welcome-to-the-new- insights%2Fperspectives%2Fperspectives-welcome-to-the-newbiogen.html&esheet=51063452&newsitemid=20150323005258&lan=enUS&anchor=read+a+letter+about+today%27s+announcement&index=2&md5=d93c551f2e79ba730c7eb78f68c065a8 [5] http://cts.businesswire.com/ct/CT? id=smartlink&url=http%3A%2F%2Fwww.biogen.com&esheet=51063452&newsitemid=20150323005258&lan=enUS&anchor=www.biogen.com&index=3&md5=31ed6fa51a713c94393aa2aff6779556 [6] http://cts.businesswire.com/ct/CT? id=smartlink&url=http%3A%2F%2Fwww.biogen.com&esheet=51063452&newsitemid=20150323005258&lan=enUS&anchor=www.biogen.com&index=4&md5=adc6b471628b4f143a986884941238ad [7] mailto:[email protected] [8] mailto:[email protected]
© Copyright 2024 ExpyDoc
